Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Vidhya Srinivasan aims to drive the integration of AI innovations into Google’s shopping and payments ecosystem.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback